The B7H1 and GITRL molecules may play an important role in TGF-beta-induced Treg expansion of lung cancer microenvironment.

Anti-PD-1/PD-L1 therapy inhibited CMT167 orthotopic lung tumors by 95%. .Silencing PD-L1 expression in CMT167 cells resulted in smaller orthotopic tumors that remained sensitive to anti-PD-L1 therapy, whereas implantation of CMT167 cells into PD-L1(-) mice blocked orthotopic tumor growth, indicating a role for PD-L1 in both the cancer cell and the microenvironment.

Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis.

B7-H1 may have a role in antitumor immune responses in non-small cell lung cancer

the expression rate of PD-L1 in non-small cell lung cancer was associated with histological types and overall survival

high levels of programmed death ligand-1 is associated with sarcomatoid lung carcinomas.

Studies indicate that PD-1/PD-L1 antibodies, considered as drug of the year 2013, showed results in melonoma, renal cancer and lung cancer.

Low expression of PD-L1 is associated with small cell lung cancer.

B7-H1 and B7-H3 are independent predictors of poorer survival in patients with non-small cell lung cancer.

PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma is associated with an increased number of CD8(+) tumor infiltrating lymphocytess and increased MET expression.

Low PD-L1 expression is associated with non-small lung cancer.

Data indicate that pulmonary pleomorphic carcinoma (PC) very frequently express CD274 antigen (PD-L1) and CD273 antigen (PD-L2).

Plasma levels of sPD-L1 are significantly increased in non small cell lung cancer patients, especially those with adenocarcinoma.

PD-L1 copy number gain is present in approximately five percent of non-small cell lung cancer with a slight preference to squamous cell carcinoma.

High PD-L1 expression is Correlated with Non-Small Cell lung cancer.

Objective determination of PD-L1 protein levels in lung neoplasms reveals heterogeneity within tumors and prominent interassay variability or discordance.

Immune checkpoint inhibitors, particularly those targeting PD-1 and PD-L1 are clinically active for the treatment of lung cancer and represent an exciting step forward in lung cancer therapy.

IL-27 induced IDO or PD-L1 expression in monocytes and in human PC3 prostate and A549 lung cancer cells

this study shows that PD-L1 expression in tumor cells markedly increased in non-small-cell lung cancer patients after gefitinib treatment

Genetic amplification of the PD-L1 gene was correlated with Non-Small Cell lung cancer.

Data suggest signaling via CD279/PDCD1 and its ligand CD274/PD-L1 is effective chemotherapy target in non-small cell lung cancer; PD-L1 is best currently available immunohistochemistry biomarker for response to immune checkpoint inhibitors. [REVIEW]

Both PD-L1 copy number gains and expression were associated with smoking-related lung tumors and predicted poor prognosis.

PD-L1 expression is not a prognostic factor in surgically resected lung adenocarcinoma patients.

PD-L1 protein expression was significantly higher in smoking-associated adenocarcinoma and in EGFR mutation-negative adenocarcinoma. PD-L1 protein expression was associated with poor survival in patients with lung adenocarcinoma.

Detailed evidence on the frequency of PD-L1 expression in surgically resected small cell lung cancer.

The study demonstrated that PD-L1 overexpression was associated with decreased overall survival in Asian patients with non-small cell lung cancer. (Meta-analysis)

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.

PD-L1 expression was associated with high proliferative activity and the EMT phenotype in adenocarcinoma but not in squamous cell carcinoma of the lung. PD-L1 expression was a significant poor prognostic factor in patients with lung adenocarcinoma.

This study showed that the brain metastases of small cell lung cancer harbor an active immune microenvironment with presence of various tumor infiltrating lymphocytes subsets and expression of the immune suppressive molecule PD-L1.

PD-L1, IDO-1, and B7-H4 are differentially expressed in human lung carcinomas and show limited co-expression. While PD-L1 and IDO-1 are associated with increased tumor-infiltrating lymphoycte and IFN-gamma stimulation, B7-H4 is not.

Epithelial mesenchymal transition phenotype is related to PD-L1 overexpression in lung adenocarcinoma cells.

Data demonstrate that PD-L1 can affect tumor cell survival by promoting cell proliferation and preventing cell apoptosis. Its high expression is associated with EGFR mutations in non-small cell lung cancer (NSCLC).

We identified that there are significant differences between the tumor microenvironment of paired primary lung cancers and brain metastases. When physicians decide to treat patients with lung cancer with a PD-1 or PD-L1 inhibitor, they must do so in the context of the spatial and temporal heterogeneity of the tumor microenvironment

PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in non-small cell lung cancer.

PD-L1 expression in resected lung adenocarcinomas is frequently observed in the presence of CTL/Th1 microenvironment, in particular in those with KRAS mutations or no common molecular alterations

No correlation between PD-L1 expression and survival in non-small cell lung carcinomas.

cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of small cell lung cancer cells under cisplatin selection.

High PD-L1 expression is associated with Small Cell lung cancer.

Avelumab, a fully human anti-PD-L1 mAb, showed accumulation in PD-L1-expressing lung cancer cells and could be used in near infrared photoimmunotherapy.

Report immunohistochemical detection of PD-L1 in non-small cell lung cancers and head and neck squamous cell carcinomas.

in a population of patients with non-small-cell lung cancer, the pattern of PD-L1 expression was heterogeneous, represented by two distinct cell types: the tumor cell (higher frequency) and IICs (lowest frequency). Positive PD-L1 expression was observed in 37.9% of tumor cells and in IICs of 24.3% of tumors.

High CD274 expression is associated with response to chemotherapy in Carcinoma, Non-Small-Cell lung.

We investigated tumor-infiltrating CD4 and CD8 T cells and the expression of PD-L1, Galectin-9, and XAGE1 in stage I to IIIA lung adenocarcinomas using a tissue microarray to deduce their contribution to overall survival, and our data showed that PD-L1 expression was a positive indicator, whereas Galectin-9 and XAGE1 expression was negative.

High PDL1 expression is associated with lung Adenocarcinomas and Nodal Metastases.

PD-L1 underexpression is associated with Non-Small-Cell lung cancer.

High PD-L1 expression is associated with Non-Small-Cell lung cancer.

Among 12 SNPs investigated, PD-L1 rs4143815C>G, rs822336G>C, and rs822337T>A were significantly associated with worse survival outcomes in multivariate analyses in early stage non-small cell lung cancer.

MAPK signaling may control the expression of PD-L1 and several genes related to enhanced cell motility. Our findings suggest that MAPK, along with STAT3, is important for determining PD-L1 expression, which could be useful for targeted therapies against lung cancers.

We found that high PD-L1 expression was a poor prognostic factor in the smokers with lung adenocarcinomaor the patients with wild-type EGFR, whereas it was not the case in those who never smoked or those with EGFR mutation, implying the importance of adenocarcinoma driver mutations and etiology.

The expressions of PD-1 and PD-L1 may be associated with the occurrence and development of pulmonary carcinoids.

This work provides evidence that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti-PD-1/PD-L1 immunotherapy

Our study found substantial inconsistencies for the percentages of cells staining positive for PD-L1 among different tissue microarray cores in many cases of both lung adenocarcinoma and squamous cell carcinoma.

PD-L1 immunohistochemistry is not a prognostic factor in early stage non-small cell lung carcinoma patients

PD-L1 overexpression is more frequently observed in male patients and smokers in lung adenocarcinoma. PD-L1 expression is an indicator of worse prognosis in surgically resected lung adenocarcinoma patients.

High PD-L1 expression correlated with poor prognosis and may provide a rationale for immunotherapy for high-grade small cell lung cancer

high PD-L1 expression and poor prognosis observed in patients with surgically resected squamous non-small-cell lung cancer (NSCLC) as compared with non-squamous NSCLC; results support the identification of patient subsets that most likely respond to anti-PD-1 therapy as the first step in precision medicine

non-small cell lung cancer with KRAS mutations showed a trend for higher frequency of positive PD-L1 expression (meta-analysis).

PD-1 and PD-L1 protein expression and their correlation with tumor-in fi ltrating lymphocytes (TILs), and association with survival in non-small cell lung cancer, were examined.

A previously unrecognized central role for MUC1-C in integrating PD-L1 activation with suppression of immune effectors and poor clinical outcome in non-small-cell lung cancer.

This study provides the preclinical rationale for the combined blockade of PD-1/PD-L1 and C5a to restore antitumor immune responses, inhibit tumor cell growth, and improve outcomes of patients with lung cancer

PD-L1 overexpression is associated with poor prognosis and is positively correlated with EGFR expression but inversely correlated with HER2 expression in non-small-cell lung cancer.

PD-L1(+) lung adenocarcinoma cases showed convergence and cavitation more frequently than did PD-L1(-) cases

PD-L1 expression is detectable in two distinct cell populations in the peripheral blood of lung cancer patients and is associated with worse survival.

KRAS mutation could induce PD-L1 expression through p-ERK signaling in lung adenocarcinoma

We showed that tumor PD-L1 expression decreased in patients with non-small cell lung cancer who received chemoradiotherapy, and radiation resistance might be due to pre-treatment PD-L1 expression

B7-H3 protein is expressed in the majority of NSCLCs and is associated with smoking history. High levels of B7-H3 protein have a negative prognostic impact in lung carcinomas. Coexpression of B7-H3 with PD-L1 and B7-H4 is relatively low, suggesting a nonredundant biological role of these targets.

This study showed significant heterogeneity of PD-L1 expression in both adenocarcinoma and squamous cell lung carcinoma samples, especially in the immune cell compartment.

PD-L1 expression was measured in paired tumor tissue samples collected at different dates and lesions from non-small cell lung cancer patients; there was a statistically significant correlation in PD-L1 proportion scores, with a 67% concordance rate when samples were categorized into positive and negative PD-L1 expression groups

The present study demonstrated that the functional polymorphisms of the miRNA-binding sites in the 3'-UTR region of the B7-H1 gene were significantly associated with higher risks of lung cancer, distant metastasis, lymph node metastasis and deep infiltration (rs2297136 and rs4742098).

The Hippo effector YAP plays a crucial role in linking the PD-L1 and EGFR-TKI resistance by directly regulating the expression of PD-L1 in lung cancer cells.

The prognostic impact of PD-L1 expression on tumor cells in lung Adenocarcinoma was distinct according to concurrent HLA class I expression status.

Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative non-small cell lung cancer

We describe a subset of non-small-cell lung cancer patients who had JAK2 amplifications resulting in high expression of PD-L1

Data suggest that expression of tumor biomarker CD274 in both tumor cells and tumor-infiltrating immune cells correlates with subsets of NSCLC; high expression of CD274 in lung adenocarcinoma subsets correlates with high histologic grade and solid subtype; high expression of CD274 in subsets also correlates with high smoking pack-years. (NSCLC = non-small-cell lung carcinoma)

Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.

PD-L1 overexpression is an unfavorable prognostic marker in non-small cell lung cancer.

This is the first U.S. Food and Drug Administration approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval expands the pembrolizumab indication in second-line treatment of lung cancer to include all patients with programmed death-ligand 1-expressing non-small cell lung cancer.

PD-L1 expression and PD-L1 SNPs were associated with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.

increased PD-L1 expression was associated with poor prognosis in lung cancer patients. However, PD-L1 expression was not correlated with ALK rearrangement and KRAS mutations (meta-analysis).

High PD-L1 expression was associated with adverse prognosis in pulmonary squamous cell carcinoma.

Increased BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signaling.

we demonstrated the prevalence and clinicopathological characteristics of tumor PD-L1 positivity in lung HGNET (i.e., SCLC and LCNEC) and the association of tumor PD-L1 positivity with lower mortality in lung HGNET.

Globo H expression was correlated with specific driver mutations in non-small cell lung cancer (NSCLC) tumors, as well as programmed death-ligand 1 (PD-L1).

intratumoral heterogeneity of PD-L1 expression was frequently observed in cases of lung cancer. Thus, multiple tumor biopsy specimens may be needed to accurately determine the PD-L1 expression status

Programmed cell death 1 ligand 1 protein (PD-L1) expression significantly correlates with overall mutational load and KRAS protein mutational status in pulmonary sarcomatoid carcinomas.

results indicate that lung cancer cell lines with EGFR mutations (parental cells) do not harbor high PD-L1 protein expression. In addition, EGFR phosphorylation affects PD-L1 expression after acquisition of resistance to EGFR-TKIs.

High PD-L1 expression is associated with lung Adenocarcinoma.

-L1 immunopositivity was seen in a quarter of non-small cell lung carcinomas patients in India. PDL1 positivity on immune cells may be associated with better prognosis in resected non-small cell lung carcinomas

The combination of PD-L1 and CD8+ tumor infiltrating lymphocytes density, instead of PD-L1 alone, suggested impressive prognostic values in Chinese patients with surgically resected non-small cell lung cancer (NSCLC). Less than half of patients with resected NSCLC experienced inconsistent PD-L1 expression between primary and metastatic lesions.

PD-L1 expression was related to high glucose metabolism in small-sized non-small cell lung cancer (NSCLC).

Lower PD-L1 expression in the tumor and in the tumor-associated macrophages seems to be associated with significantly better overall survival in surgically resected stage I lung cancer.

High expression of PDL1 correlates with non-small cell lung cancer.

This study provides important evidence of higher levels of agreement of PD-L1 expression in pulmonary metastasis compared with in multiple primary lung cancer, and high positivity of PD-L1 expression in pulmonary metastatic lesions with wild-type EGFR in an Asian population.

Taken together, a stiff substrate enhanced PD-L1 expression via actin-dependent mechanisms in lung cancer cells. It is suggested that stiffness as a tumor environment regulates PD-L1 expression, which leads to evasion of the immune system and tumor growth.

Data indicate that nuclear H2A histone family, member X protein (gammaH2AX) expression is positively associated with the programmed death-ligand 1 (PD-L1) expression in lung squamous cell carcinoma.

The PD-L1 expression in brain metastases from non-small cell lung cancer may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects.

PD-L1 expression was negative prognostic factor for progression free survival and overall survival after concurrent concurrent or sequential chemotherapy in locally advanced non-small cell lung cancer.

Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer

PD-L1 protein expression was a significant independent predictor of poor outcome in non-small cell lung cancer patients.

High levels of CD274 are associated with Non-small Cell lung cancer.

Findings suggest that the PD-1/PD-L1 pathway is activated in the microenvironment of pulmonary high-grade neuroendocrine carcinoma and correlated with a higher mutation burden.

This study compares the differences of PD-L1 expression and CD8+ tumor-infiltrating lymphocyte density, two major response biomarkers of PD-1/PD-L1 blockade, between paired primary and brain metastatic lesions in advanced non-small cell lung cancer. Among primary lesions or brain metastases, only a small number of patients harbored common PD-L1 expression on both tumor cells and tumor-infiltrating immune cells.

High CD274 expression is associated with non-small cell lung cancer.

this study describes PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

this study shows that PD-L1 expression is associated with RAS/TP53 mutations in lung adenocarcinoma

High expression of CD274 is associated with pleomorphic carcinoma of the lung.

PD-L1 expression is a prognostic factor related with poor survival among patients that developed non-small cell lung cancer.

Study demonstrated the distinct prognostic values of POLE mutation and PD-L1 expression in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Importantly, the combination of POLE mutation and PD-L1 expression as a favorable indicator for improved OS of LUAD patients and the activation of antitumor immune system.

High expression of PD-L1 is associated with pulmonary metastasis in colorectal cancer.

The inhibition of PTEN also reduced the cancer effects of CD4+ T cells on non-small cell lung cancer (NSCLC) cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4+ T cells in human NSCLC through PD-L1 expression via the PTEN pathway.

Thus, PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma was associated with BIM and VEGFA mRNA expression and with shorter PFS after gefitinib therapy.

Study in cohort of Asian patients revealed that PD-L1 expression varied with histologic subtype and genomic alteration status in lung adenocarcinoma, and activation of the PD-L1 pathway may be a poor prognostic factor especially in early stage lung adenocarcinoma.

Low soluble Programmed Cell Death Ligand 1 is associated with low response to Nivolumab Therapy in Non-Small-cell lung cancer.

PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.

We show that MET activation promotes the expression of several negative checkpoint regulators of the immunoresponse, including PD-L1. In addition, we report inactivation of JAK2 in lung cancer cells that prevented the response to IFNgamma.

High PD-L1 expression is associated with pulmonary metastases in head and neck squamous cell carcinoma.

High CD274 expression is associated with non-small cell lung cancer.

summarizes current literature data on the heterogeneity of PD-L1 expression and the relationship with such factors and with clinicopathological features of non-small cell lung cancer.[review]

Results suggest that indoleamine 23-dioxygenase 1 (IDO1) and programmed cell death-ligand 1 (PD-L1) co-expression may define an aggressive form of lung adenocarcinoma.

Treatment of lung cancer cell lines with a COX2 inhibitor had no impact on PD-L1 expression.

Demonstrate discordance between PD-L1 RNA levels and protein expression in non-small cell lung cancers.

The accumulation of 2-Deoxy-2-[fluorine-18] fluoro-d-glucose is closely associated with the expression of programmed death ligand-1 (PD-L1) in lung adenocarcinoma.

Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced lung Non-Small Cell lung Carcinomas.

The results implied that both squamous and glandular components of adenosquamous carcinoma of the lung may share the same oncogenic driver pathway for carcinogenesis, which is reflected in the patterns of expression of PTEN and PD-L1.

Study is the first report to elucidate PD-L1 expression of uncommon EGFR mutation-positive non-small-cell lung cancer (NSCLC). The characteristics of patients harboring uncommon EGFR mutations differ from those of patients with common EGFR mutations. PD-L1 tumor proportion score was significantly higher in uncommon compared with common EGFR mutation-positive NSCLC.

The Clinicopathological and Molecular Associations of PD-L1 expression in Non-small Cell lung cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.

High PD-L1 levels and tumor infiltrating lymphocyte activation are associated with non-small cell lung cancer.

PD-L1 expression seemed to increase according to pathologic tumor progression, suggesting a worse postoperative prognosis in non-small cell lung carcinoma patients.

Higher serum concentration of PD-L1 on admission was associated with higher risk of no response to chemotherapy or lung cancer caused death.

Results show that PD-L1 expression was positively regulated by and correlated with CD147 expression in human non-small cell lung cancer (NSCLC) cell lines.

EZH2-expressing lung adenocarcinomas were shown to express the PD-L1 protein more frequently than were nonexpressing lesions. This study provides the first evidence of a possible association between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma.

PD-L2-positive lung adenocarcinomas are less radiologically malignant and invasive than their PD-L1-positive counterparts

High CD274 expression is associated with metastatic Lymph Nodes in lung cancer.

the type I IFN receptor signal elicits an increase in PD-L1 expression in lung cancer cells through IRF9-dependent and independent pathways.

Different Signaling pathways in Regulating PD-L1 expression in EGFR Mutated lung Adenocarcinoma

In the largest consecutive routine Asian non-small cell lung cancer (NSCLC) cohort analyzed to date, we found that high PD-L1 expression frequently overlapped with ROS1 rearrangement, while it negatively correlated with EGFR mutations.

Immunocytochemical staining for programmed cell death 1 ligand 1 protein (PD-L1) in diagnostic cytological smears of non-small-cell lung cancer (NSCLC) is feasible.

High CD274 expression is associated with non-small cell lung cancer.

The plasma MSC test could supplement PD-L1 tumor expression to identify a subgroup of patients with advanced lung cancer with worse ORR, PFS, and OS in immunotherapy regimens.

PD-L1 was expressed at higher levels in ALK inhibitor-resistant non-small cell lung cancer (NSCLC) cell lines than in the ALK inhibitor-naive cell line. Also, PD-L1 expression in the double-resistant cell lines was much higher than that in the single resistant cell lines. These data showed that PD-L1 expression increased following acquisition of ALK inhibitor resistance in ALK-positive NSCLC cell lines and tumors.

PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in non-small cell lung cancer (NSCLC), predominantly in the adenocarcinoma group.

low expression of PD-L1 is associated with improved prognosis in non-small-cell lung cancer

High CD274 expression is associated with lung Adenocarcinoma.

High CD274 expression is associated with lung Adenocarcinoma.

in pulmonary large cell neuroendocrine carcinoma patients with PD-L1 expression superior overall survival was observed

MAPK pathway activity plays a key role in EGF- and IFNgamma-induced PD-L1 expression in lung adenocarcinoma cells.

Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.

Study demonstrated that the presence of necrosis correlates with higher PD-L1 expression of tumor cells and PD-1 expression of immune cells in lung adenocarcinoma (LADC). Further studies are required to determine the predictive value of this observation in LADC patients receiving immunotherapy.

Therapeutic indications and predictive factors for immunotherapy with anti-PD-1 and anti-PD-L1 antibodies in non-small cell lung cancer (NSCLC) patients are very diverse. expression of PD-L1 on tumor cells and tumor mutations burden are neither the only nor the perfect predictors for immunotherapy.

Data indicate the involvement of tumor-intrinsic programmed cell death 1 ligand 1 protein (PD-L1)-signaling effectors of lung cancer.

PD-L1 expression may be not a predictor of overall survival for patients with lung adenocarcinoma.

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNgamma signaling in non-small cell lung cancer.

Assessing PD-L1 expression Level by Radiomic Features From PET/CT in Nonsmall Cell lung cancer Patients: An Initial Result.

this study shows a strong correlation of PD-L1 positive tumor cells between primary lung adenocarcinoma cases and their corresponding brain metastases

Frequent genetic alterations in Chinese lung squamous cell carcinoma patients had no impact on PD-L1 expression but PIK3CA amplification and KEAP1 mutation were independently associated with significantly lower CD8+ tumor-infiltrating lymphocyte density (P < 0.001, P = 0.005, respectively).

PD-L1 mRNA expression correlates to alterations in non-small cell lung cancer disease progression.

The present results indicate that EZH2 regulates the immunosuppressive molecule PD-L1 expression via HIF-1alpha in non-small cell lung cancer cells.

Treatment benefits of chemoimmunotherapy (CIT) differed between PD-L1-high and PD-L1 low and PD-L1-high and PD-L1-negative advanced non-small-cell lung cancer. Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.[meta-analysis]

PD-L1 was present on exosomes isolated from the plasma of patients with non-small cell lung cancer, and its abundance in exosomes was correlated with PD-L1 positivity in tumor tissues. Exosomes can impair immune functions by reducing cytokine production and inducing apoptosis in CD8(+) T cells. tumor-derived exosomes expressing PD-L1 may be an important mediator of tumor immune escape.

Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.

PD-L1 expression in squamous cell lung carcinoma was correlated with severity of emphysema in tumor cells (TC)0, 1, 2 vs. TC3 and more frequent in none-mild emphysema than moderate-severe emphysema.

plasma levels of PD-L1 are independent of the expression of PD-1/PD-L1 in non-small cell lung cancer tumor tissue and, when combined with other clinical-pathological parameters, allow for the identification of clusters with different outcomes

The lung adenocarcinomas with ground-glass opacity were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.

High CD274 expression is associated with non-small cell lung cancer.

this study is the largest to evaluate the association between PD-L1 expression and clinicopathological and molecular features in lung cancer with a highly prevalent EGFR mutation.

Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.

A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung.

Data suggest that PD-L1 expression is quite heterogenous in mixed lung adenocarcinomas and adenosquamous lung carcinomas, partly contributing to explaining the discrepant results between biopsy and surgical resections and discordant clinical effectiveness in regard to PD-L1-positive or negative adenocarcinoma diagnosed on cytology/small biopsy.

CD44 Promotes PD-L1 expression and Its tumor-Intrinsic Function in Breast and lung cancers.

Is there any correlation between spectral CT imaging parameters and PD-L1 expression of lung adenocarcinoma?

Validation of the QR1 Antibody for the Evaluation of PD-L1 expression in Non-Small Cell lung Adenocarcinomas.

Results demonstrated that tumor-infiltrating macrophages are extrinsic regulators of tumor PD-L1 expression providing important mechanistic insight into tumor immune evasion in early lung adenocarcinoma.

Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.

Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.

circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma.

Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.

Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.

Programmed Death-Ligand 1 expression in Non-Small Cell lung Carcinoma Biopsies and Its Association with tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.", trans "Expresia ligandu receptora programovanej bunkovej smrti 1 v bio psii nemalobunkoveho karcinomu pľuc a jej asociacia s tumor infi ltrujucimi lymfocytmi a stupňom dezmoplazie.

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.

Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.

Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration to assess tumor-programmed cell death ligand-1 expression in mediastinal lymph nodes metastasized from non-small cell lung cancer.

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.

A PD-L1 tumor proportion score >/= 50% was more frequent in non-small cell lung cancer patients harboring uncommon EGFR mutations and was associated with pembrolizumab efficacy.

Pembrolizumab has activity in brain metastases from non-small-cell lung cancer with PD-L1 expression at least 1% and is safe in selected patients with untreated brain metastases. Further investigation of immunotherapy in patients with CNS disease from non-small-cell lung cancer is warranted

expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.

FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.

Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study.

Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma.

PD-L1 promotes tumor growth and progression by activating WIP and beta-catenin signaling pathways and predicts poor prognosis in lung cancer.

Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.

Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).

[Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].

PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.

Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.

Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.

CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.

Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.

Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.

Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.", trans "PD-L1.

Association between (18)F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens.

Detection of Programmed Cell Death Ligand 1 expression in lung cancer Clinical Samples by an Automated Immunohistochemistry System.

PD-L1 expression Status Predicting Survival in pulmonary Pleomorphic Carcinoma.